Pelthos Therapeutics Inc.

NYSE:PTHS

Biological Products, (No Diagnostic Substances)·DURHAM, NC

CEO

Plesha Scott M.

Summary Financials

Revenue

—

Adj. EBITDA

—

Net Income

-$7.4M

FY 2024

EPS (Diluted)

-$5.78

FY 2024

Stock Price

$23.12

+3.2%

2026-03-06

52W Range

$9.00 – $54.29

P/E Ratio

-4.0x

Market Cap

$70.8M

Cash

$100,000

FY 2023

Total Debt

—

Net Cash

$100,000

Enterprise Value

$70.7M

Debt / EBITDA

—

EV / EBITDA

—

Employees

—

Revenue

—

Adj. EBITDA

—

Net Income

-$7.4M

FY 2024

EPS (Diluted)

-$5.78

FY 2024

Stock Price

$23.12

+3.2%

2026-03-06

52W Range

$9.00 – $54.29

P/E Ratio

-4.0x

Market Cap

$70.8M

Cash

$100,000

FY 2023

Total Debt

—

Net Cash

$100,000

Enterprise Value

$70.7M

Debt / EBITDA

—

EV / EBITDA

—

Employees

—